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Objectives The aim of this study was to evaluate the impact of ischemia-guided (IG) revascularization.
Background The importance of IG revascularization has not been well-determined.
Methods The outcomes of IG revascularization, in which revascularization was performed in the matched coronary artery
with the perfusion abnormality on myocardial perfusion image (MPI), were retrospectively compared with those
of non-IG revascularization in a registry of 5,340 patients with multivessel coronary disease comprising 2,587
percutaneous coronary interventions (PCIs) with drug-eluting stents and 2,753 coronary artery bypass graft
(CABG) surgeries after adjustment with inverse-probability-of-treatment weighting.
Results The MPI was performed in 42.3% of patients, and IG revascularization was performed in 17.3%, including 12.4%
in PCI and 21.8% in CABG patients (p  0.001). The incidence of major adverse cardiac and cerebrovascular
events (MACCE) including death, myocardial infarction, stroke, or repeat revascularization was significantly lower
in the IG than in the non-IG group (16.2% vs. 20.7%; adjusted hazard ratio [aHR]: 0.73; 95% confidence interval
[CI]: 0.60 to 0.88; p  0.001), primarily driven by the lower repeat revascularization rate (9.9% vs. 22.8%; aHR:
0.66; 95% CI: 0.49 to 0.90; p  0.009). Subgroup analysis showed that IG reduced the risk of MACCE in PCI
(17.4% vs. 22.8%; aHR: 0.59; 95% CI: 0.43 to 0.81; p  0.001) but not in CABG (16.0% vs. 18.5%; aHR: 0.87;
95% CI: 0.67 to 1.14; p  0.31) patients.
Conclusions Ischemia-guided revascularization with MPI, particularly in PCI-treated patients, seems to decrease the risk of
repeat revascularization and MACCE for patients with multivessel disease. (J Am Coll Cardiol 2012;60:
181–90) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.061The major purposes of stress testing are to identify high-risk
patients who might require invasive angiography or revas-
cularization and to objectively evaluate ischemia in patients
with coronary artery disease (1). In the absence of disabling
symptoms, evidence of ischemia has been recognized as
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Without objective determination of ischemia, complete
angiographic revascularization might not be superior to
reasonable incomplete revascularization (1,2). Myocardial
perfusion imaging (MPI) with stress single-photon emis-
sion computed tomography (SPECT) has been used to
diagnose inducible ischemia and to predict prognosis of
patients with coronary artery disease, and SPECT results
have shown fair concordance with the prevalence of signif-
icant ischemia (3).
See page 191
In addition to the diagnostic and prognostic utility of
MPI, the area of perfusion abnormality can be used to
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dium and indicate the functional
stenosis of the matched epicardial
artery (4). The FAME (Flow Re-
serve versus Angiography for
Multivessel Evaluation) study re-
ported that ischemia-guided (IG)
percutaneous coronary interven-
tion (PCI) with fractional flow
reserve (FFR) to localize isch-
emic area resulted in a lower
1-year incidence of death, myo-
cardial infarction (MI), or repeat
revascularization than conven-
tional angiography-guided PCI
for patients with multivessel dis-
ease (MVD) (5,6). To date, how-
ever, little is known about the
clinical implications of MPI for
IG revascularization in the treat-
ment of MVD. Therefore, we
evaluated the prognostic impact
of IG revascularization with
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
DES  drug-eluting stent(s)
FFR  fractional flow
reserve
IG  ischemia-guided
LAD  left anterior
descending artery
MACCE  major adverse
cardiac and cerebrovascular
event(s)
MI  myocardial infarction
MPI  myocardial perfusion
imaging
MVD  multivessel disease
PCI  percutaneous
coronary intervention
SPECT  single-photon
emission computed
tomography
Figure 1 Study Flow Diagram
All values are presented as n (%). CABG  coronary artery bypass graft; MI  myo
PCI  percutaneous coronary intervention; Revas(c)  revascularization; SPECT MPI in patients with MVD who underwent PCI with
drug-eluting stents (DES) or coronary artery bypass graft
(CABG) surgery.
Methods
Patients. The study population was a part of the Asan
Multivessel Registry and included consecutive patients with
MVD who underwent PCI with DES or CABG (Fig. 1)
(2). Patients who presented with ST-segment elevation MI
and/or cardiogenic shock or for whom no clinical follow-up
information was available were excluded. The procedures
and follow-up have been described previously (2). During
the study period, DES was the default stent for PCI in
patients with MVD. After DES implantation, dual anti-
platelet therapy with aspirin and clopidogrel was recom-
mended for at least 1 year. The institutional review board of
our institution approved the use of clinical data for this
study, and all patients provided written informed consent
for enrollment in our registry.
Stress SPECT protocol. IMAGING. Thallium-201 (Tl-201)
PECT was the default stress MPI during the study period.
mages were acquired with a standardized protocol (7).
l infarction; MPI  myocardial perfusion image;
-photon emission computed tomography.cardia
single
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0.14 g kg1min1 for 6 min. Three minutes after the
initiation of the adenosine infusion, a 92.5- to 148-MBq
dose of Tl-201, depending on the body weight of each
patient, was injected intravenously. Five minutes after adeno-
sine infusion, post-stress MPI was acquired with a 2-head
gamma camera (Ecam, Siemens, Munchen, Germany)
equipped with low-energy, all-purpose collimators. Specific
acquisition parameters were dependent on the camera. The
images were evaluated by experienced nuclear medicine
physicians.
INTERPRETATION. The MPI cohort included 2,259
(42.3%) patients, all of whom underwent Tl-SPECT within
1 year before index revascularization. Analysis of relative
perfusion distribution was assessed in 17 myocardial seg-
ments (3). The SPECT study was considered to be abnor-
mal if the summed stress score was 3 or greater. For the
purpose of this study, the areas of perfusion abnormalities
were classified into LAD and non-LAD territories. Patients
with perfusion abnormalities in the anterior, anteroseptal, or
anteroapical walls were regarded as having LAD ischemia,
whereas patients with perfusion abnormalities in other
segments were regarded as having non-LAD ischemia.
When adjunctive markers of ischemia such as an increased
stress–rest left ventricular cavity ratio or increased lung
uptake were found, especially in the presence of abnormal
MPI, the patient was assumed to have ischemia in both
LAD and non-LAD territories.
MPI was undertaken before (A) or after (C) diagnostic
angiography. After diagnostic angiography (B), patients
underwent revascularization with (C) or without (J) MPI
test. After diagnostic angiography and/or MPI examination,
revascularization was performed in the vessel matched with
abnormal MPI (D, G), in the vessel mismatched with
abnormal MPI (E, H), and in the vessel with normal MPI
(F, I). Ischemia-guided revascularization was defined as an
attempted revascularization with PCI or CABG in all
vessels matched with the perfusion abnormalities of MPI
during the index hospital stay or within 30 days after the
index procedure but before a new MI or urgent revascular-
ization. Non-IG revascularization was defined as revascu-
larization of non-ischemic vessel, non-revascularization of
ischemic vessel, or revascularization without MPI (subgroup J).
If any vessel was revascularized without ischemia guidance,
the patient was categorized into the non-IG group.
Angiographic analysis. The angiographic cohort consisted
of the 3,352 (62.8%) patients for whom we had available
angiograms. Angiographic complexity was assessed with
dedicated angiographic software (CAAS version 5, Pie
Medical, Maastricht, the Netherlands) in the angiographic
core laboratory of the CardioVascular Research Foundation,
Seoul, Korea, according to the SYNTAX (Synergy Between
PCI With Taxus and Cardiac Surgery) classification (8).
Clinical endpoints. The primary endpoint of this study
was the rate of major adverse cardiac and cerebrovascularevents (MACCE), consisting of death, MI, stroke, or repeat
revascularization. Secondary endpoints included the indi-
vidual endpoints of MACCE and the composite of death,
MI, or stroke. Deaths were considered cardiac unless an
unequivocal, noncardiac cause was established. Myocardial
infarction as a complication was defined as either at index
admission (defined as new Q-wave after index treatment) or
at follow-up and requiring subsequent hospital stay (defined
as new Q- or non–Q-wave), as described (9). Repeat
revascularization included target vessel revascularization and
non-target vessel revascularization. Stroke, as indicated by
neurologic deficits, was confirmed by a neurologist on the
basis of imaging modalities. Procedural success was defined
as the attainment of Thrombolysis In Myocardial Infarction
(TIMI) flow grade of more than 1 without the occurrence of
procedure-related in-hospital MACCE. In the PCI group,
stent thrombosis was defined as the definite or probable
occurrence of a thrombotic event, according to the Aca-
demic Research Consortium classification (10). All out-
comes of endpoints were carefully verified and adjudicated
by independent clinicians.
Clinical, angiographic, procedural or operative, and out-
come data were prospectively recorded in the dedicated PCI
and surgical databases by independent research personnel.
Patients were clinically followed-up at 1, 6, and 12 months
and annually thereafter, via office visit or telephone contact.
To validate follow-up mortality, information about vital
status was obtained through December 2009 from the
National Population Registry of the Korea National Statis-
tical Office with the unique personal identification number
of each patient.
Statistical analysis. Differences in baseline clinical and
angiographic characteristics and procedural findings were
compared with the Wilcoxon rank sum test for continuous
variables and the chi-square or Fisher exact test for categor-
ical variables, as appropriate. Survival curves were con-
structed with the Kaplan-Meier method and compared with
the log-rank test. Patients were censored at 5 years (1,800
days) or when events occurred.
Differences between the IG and non-IG groups in
risk-adjusted, long-term rates of study outcomes were as-
sessed with multivariable Cox proportional hazards regres-
sion analyses. The proportional hazards assumption was
confirmed by examination of log (-log [survival]) curves and
by testing of partial (Schoenfeld) residuals (11), and no
relevant violations were identified. We also adjusted for
differences in patient baseline characteristics with weighted
Cox proportional hazards regression models with inverse-
probability-of-treatment weighting (12). The primary ad-
justment was performed in all patients with the clinical
covariates of age, sex, body mass index, diabetes mellitus,
hypertension, current smoking, hyperlipidemia, left ventric-
ular ejection fraction, atrial fibrillation, history of MI,
cerebrovascular disease, chronic lung disease, peripheral
vascular disease, congestive heart failure, prior coronary
angioplasty, and acute coronary syndrome. This was fol-
r
n
c
t
t
p
P
a
r
b
p
o
b
o
H
r
a
n
a
i
i
p
c
r
r
c
v
184 Kim et al. JACC Vol. 60, No. 3, 2012
Ischemia-Guided Revascularization July 17, 2012:181–90lowed by a second adjustment in the angiographic cohort
with the covariates of clinical factors, as in the preceding
text, and angiographic factors including stenosis in the left
main, LAD, left circumflex artery, and right coronary artery;
3-vessel disease; any total occlusion; and SYNTAX score.
The subgroups of patients sorted according to various
clinical and angiographic characteristics were analyzed
after adjustment with the multivariable Cox model with
clinical factors as covariates. Interactions between factors
associated with IG and subgroups were tested by incor-
poration of formal interaction terms in the multivariable
Cox model.
Matched propensity score analyses were used to ascertain
the results of primary analysis (13), due to the possibility of
biased effect estimates in observational studies. Patients
between the 2 groups were matched in 1:1 on the logit of
the propensity score with a caliper of width 0.2 of the SD of
the logit of the propensity score. Matching was performed
with %GMATCH SAS macro (Mayo Clinic, Rochester,
Minnesota). Matching balance was assessed by standardized
and absolute differences on each covariate (14). Cox pro-
portional hazard models were used to calculate hazard ratios
of outcomes comparing the matched groups. All reported p
values are 2-sided, and p values 0.05 were considered
statistically significant. The SAS software (version 9.1, SAS,
Cary, North Carolina) and the R programming language
were used for statistical analyses.
Results
Patient characteristics. From the registry, we enrolled
5,340 patients, including 2,587 who underwent PCI and
2,753 who underwent CABG (Table 1). Of these patients,
922 (17.3%) underwent IG revascularization, including 322
(12.4%) in the PCI and 600 (21.8%) in the CABG (p 
0.001) cohorts. The MPI was performed a median 15 days
(interquartile range [IQR]: 6 to 44 days) before the index
procedure. In the PCI group, IG patients presented with
more stable coronary symptoms, underwent more treadmill
tests, and received fewer DESs than non-IG patients. In the
CABG group, IG patients were younger; had a higher rate
of unstable symptoms; had lower rates of hypertension,
smoking, and cerebrovascular disease; had lower left ven-
tricular function; underwent more treadmill tests; and re-
ceived a higher number of graft conduits.
The angiographic cohort consisted of 3,352 patients,
including 2,023 (78.2%) PCI and 1,329 (48.3%) CABG
patients, with angiograms available for retrospective analy-
sis. In the PCI group, IG patients had a lower rate of LAD
diseases and a higher rate of total occlusions than non-IG
patients, whereas in the CABG group, IG patients had a
higher rate of total occlusions than non-IG patients.
The characteristics of perfusion abnormalities in the MPI
cohort are presented in Table 2. The IG patients had higher
rates of perfusion abnormalities in the LAD and non-LAD
territories, higher rates of reversible defects and larger perfusion rdefects in the both PCI and CABG groups. However, the 2
groups had a similar prevalence of patients with fixed defects.
Clinical outcomes. UNADJUSTED INCIDENCES. Procedural
success was obtained in 5,258 (98.5%) patients comprising 905
(98.2%) in the IG and 4,353 (98.5%) in the non-IG groups
(p  0.40). In PCI (99.4% vs. 99.5%, p  0.69) and CABG
(97.5% vs. 97.5%, p  0.96) patients, the procedural success
rate did not differ between the IG and non-IG groups.
The median follow-up durations were 60 months (IQR:
48 to 60 months) in the IG group and 53 months (IQR: 37
to 60 months) in the non-IG group (p  0.001). Figure 2
shows the Kaplan-Meier incidence curves of the primary
and secondary endpoints in the IG and non-IG groups in
the overall, PCI, and CABG cohorts. Table 3 presents the
numbers and cumulative incidences of events in the IG and
non-IG groups in the PCI and CABG patients. The
primary endpoint of MACCE was significantly lower in the
IG than in the non-IG group in overall and PCI patients.
Of the individual endpoints of MACCE, the incidence of
repeat revascularization was significantly lower in the IG
than in the non-IG group in PCI patients. However, the
incidence of death, MI, or stroke did not differ between the
IG and non-IG groups in the overall, PCI, or CABG
cohorts. In the CABG cohort, there was no difference
between the IG and non-IG groups in the rate of any event.
ADJUSTED RISKS. Table 4 presents the adjusted hazard
atios and 95% confidence intervals of IG, as compared with
on-IG, for MACCE; repeat revascularization; and the
omposite of death, MI, or stroke. After adjustments with
he multivariate Cox model and inverse-probability-of-
reatment weighting method, the hazard ratios for the
rimary endpoint of MACCE favored IG in overall and
CI patients. However, the risk of MACCE was not
ssociated with IG in CABG patients. The risk of repeat
evascularization was also lower with IG in overall and PCI
ut not in CABG patients. In both PCI and CABG
atients, IG was not associated with the risk of the composite
f death, MI, or stroke. There was no significant interaction
etween IG and treatment type (PCI or CABG) for the risks
f MACCE and the composite of death, MI, or stroke.
owever, we observed a significant interaction for the risk of
epeat revascularization. In the second adjustment for the
ngiographic cohort, the favorable pattern of hazard ratios was
ot changed in overall, PCI, and CABG patients.
In the propensity matching analyses, the IG group was
ssociated with the reduction in risks of repeat revascular-
zation and MACCE in 321 pairs of PCI patients, but not
n 596 pairs of CABG patients (Table 5). When the
atients were separated according to the subgroup classifi-
ations as in Figure 1, there was a tendency of a decreased
isk of repeat revascularization and MACCE in patients
eceiving revascularization after MPI (groups D to I)
ompared with those undergoing angiography-guided re-
ascularization without MPI (group J). In addition, IG
evascularization (group D or G) was associated with a
artery;
gery.
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ite of death, MI, or stroke, and MACCE compared with
MPI-unmatched revascularization (group E or H) among
patients receiving MPI.
Figure 3 presents the incidences and adjusted hazard
ratios of IG for MACCE in various clinical and angio-
Baseline Patient CharacteristicsTable 1 Baseline Patient Characteristics
PCI
Variable IG Non-IG
Clinical characteristics n  322 n  2,26
Age, yrs 62 (55–69) 64 (56–70
Male 226 (70.2) 1,550 (68.4)
Body mass index, kg/m2 25.2 (23.6–27.0) 25.0 (23.1–
Diabetes mellitus 120 (37.3) 727 (32.1)
Hypertension 205 (63.7) 1,339 (59.1)
Current smoker 116 (36.0) 848 (37.4)
Hyperlipidemia 114 (35.4) 750 (33.1)
Prior MI 9 (2.8) 76 (3.4)
Previous PCI 70 (21.7) 395 (17.4)
Congestive heart failure 3 (0.9) 16 (0.7)
Obstructive pulmonary disease 4 (1.2) 10 (0.4)
Cerebrovascular disease 23 (7.1) 144 (6.4)
Peripheral vascular disease 2 (0.6) 40 (1.8)
Renal failure 9 (2.8) 67 (3.0)
Atrial fibrillation 10 (3.1) 49 (2.2)
Left ventricular ejection fraction, % 60 (56–64) 60 (55–64
Clinical presentation
Stable angina 207 (64.3) 1,244 (54.9)
Unstable angina 114 (35.4) 1,004 (44.3)
Acute NSTEMI 1 (0.3) 17 (0.8)
Angiographic characteristics n  310 n  1,71
SYNTAX score 15.5 (11.0–22.0) 17.0 (11.0–
Angiographic stenosis
LAD 260 (83.9) 1,555 (90.8)
Left circumflex 202 (65.2) 1,106 (64.6)
Right coronary 229 (73.9) 1,252 (73.1)
Left main 34 (11.0) 261 (15.2)
3-vessel disease 127 (41.0) 714 (41.7)
Any total occlusion 61 (19.7) 247 (14.4)
Procedures n  322 n  2,26
Treadmill test* 113 (35.1) 431 (19.0)
Treated vessel
LAD or left main 205 (63.7) 1,768 (78.1)
Left circumflex 113 (35.1) 940 (41.5)
Right coronary 138 (42.9) 1,172 (51.7)
CABG
Number of conduits — —
Number of arterial conduit — —
Internal thoracic artery — —
Off-pump surgery — —
PCI
Number of total stents 2.0 (1.0–3.0) 2.0 (2.0–3
Length of total stents, mm 51 (32–67) 56 (33–84
Mean stent size, mm 3.1 (3.0–3.5) 3.2 (3.0–3
Values are median (interquartile range) and n (%). *Treadmill tests performed 1 year before the i
CABG  coronary artery bypass graft; IG  ischemia-guided; LAD  left anterior descending
percutaneous coronary intervention; SYNTAX  Synergy Between PCI With Taxus and Cardiac Surgraphic subgroups. A tendency of reduced risk of MACCEwas observed in most subgroups. No subgroup had a
significant interaction with regard to IG.
Discussion
The major findings of this study were: 1) fewer than one-half of
CABG
p Value IG Non-IG p Value
n  600 n  2,153
0.35 63 (56–68) 64.0 (57.0–69.0) 0.006
0.53 456 (76.0) 1,571 (73.0) 0.04
0.060 24.8 (23.1–26.5) 24.5 (22.7–26.4) 0.051
0.064 191 (31.8) 772 (35.9) 0.068
0.12 226 (37.7) 1,114 (51.7) 0.001
0.62 87 (14.5) 487 (22.6) 0.001
0.42 182 (30.3) 665 (30.9) 0.80
0.60 85 (14.2) 259 (12.0) 0.16
0.060 59 (9.8) 273 (12.7) 0.058
0.72 26 (4.3) 99 (4.6) 0.78
0.086 13 (2.2) 44 (2.0) 0.85
0.59 55 (9.2) 272 (12.6) 0.020
0.13 30 (5.0) 120 (5.6) 0.58
0.87 33 (5.5) 139 (6.5) 0.39
0.29 20 (3.3) 89 (4.1) 0.37
0.29 58 (47–63) 59 (51–64) 0.001
0.006 0.001
302 (50.3) 1,495 (69.4)
298 (49.7) 655 (30.4)
0 3 (0.1)
n  268 n  1,061
0.30 24.5 (14.0–35.4) 23.0 (13.0–31.5) 0.016
0.001 214 (79.9) 854 (80.5) 0.81
0.84 160 (59.7) 679 (64.0) 0.19
0.78 190 (70.9) 746 (70.3) 0.85
0.050 95 (35.4) 327 (30.8) 0.15
0.82 147 (54.9) 604 (56.9) 0.54
0.018 98 (36.6) 283 (26.7) 0.001
n  600 n  2,153
0.001 99 (16.5) 251 (11.7) 0.002
0.001 589 (98.2) 2,091 (97.1) 0.16
0.029 477 (79.5) 1,680 (78.0) 0.44
0.003 439 (73.2) 1,427 (66.3) 0.001
— 3.0 (3.0–4.0) 3.0 (2.0–4.0) 0.001
— 3.0 (2.0–3.0) 2.0 (1.0–3.0) 0.001
— 510 (85.0) 1,867 (86.7) 0.28
— 370 (61.7) 1,243 (57.7) 0.084
0.001 — — —
0.001 — — —
0.11 — — —
vascularization.
MI  myocardial infarction; NSTEMI  non–ST-segment elevation myocardial infarction; PCI 5
)
26.8)
)
3
22.0)
5
.0)
)
.5)
ndex repatients with MVD who underwent revascularization received
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Ischemia-Guided Revascularization July 17, 2012:181–90MPI with SPECT before the procedure; 2) fewer than one-half
of patients undergoing MPI underwent IG revascularization on
the basis of the perfusion abnormalities on MPI; 3) IG revascu-
larization decreased the 5-year risk of MACCE, primarily driven
Myocardial Perfusion Abnormalities Among Patients Undertaking MTable 2 Myocardial Perfusion Abnormalities Among Patients U
PCI
Variable IG (n  322) Non-IG (n 
Site of perfusion defects
LAD 205 (63.7) 246 (42.3
Non-LAD 199 (61.8) 236 (40.6
Reversibility
Any fixed defect 32 (9.9) 56 (9.6)
Any reversible defect 301 (93.5) 362 (62.3
Area of perfusion defect  medium 306 (95.0) 397 (68.3
Values are n (%).
Abbreviations as in Table 1.
Figure 2 Kaplan-Meier Incidence Curves Over 5 Years
IG  ischemia-guided; MACCE  major adverse cardiac and cerebrovascular evenby the reduction of repeat revascularization rate after PCI with
DES but not after CABG; and 4) safety—as reflected by the risk
of death, MI, or stroke—was comparable between IG and
non-IG patients.
rdial Perfusion Imagingaking Myocardial Perfusion Imaging
CABG
p Value IG (n  600) Non-IG (n  756) p Value
0.001 589 (98.2) 299 (39.6) 0.001
0.001 556 (92.7) 363 (48.0) 0.001
0.88 88 (14.7) 90 (11.9) 0.14
0.001 572 (95.3) 564 (74.6) 0.001
0.001 600 (100) 625 (82.7) 0.001
er abbreviations as in Figure 1.yocandert
581)
)
)
)
)ts; oth
t.
yocardia
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July 17, 2012:181–90 Ischemia-Guided RevascularizationIn making decisions on revascularization, stress tests are
strongly recommended to confirm inducible ischemia because
recent clinical trials failed to show the benefits of routine rather
than provisional revascularization for stable coronary disease
(1,15). In real-world practice, however, stress tests are infre-
quently performed, and revascularization is potentially over- or
Adjusted HRs of Ischemia-Guided Revascularization for EventsTable 4 Adjusted HRs of Ischemia-Guided Revascularization for
Population Outcomes Groups
Mult
HR 95%
All patients
Death, MI, or stroke All 0.86 0.69–1
PCI 0.84 0.54–1
CABG 0.84 0.65–1
Repeat revascularization All 0.76 0.57–1
PCI 0.56 0.37–0
CABG 1.18 0.74–1
MACCE All 0.77 0.64–0
PCI 0.61 0.45–0
CABG 0.85 0.67–1
Angiographic cohort
Death, MI, or stroke All 0.79 0.58–1
PCI 0.85 0.53–1
CABG 0.80 0.54–1
Repeat revascularization All 0.71 0.50–1
PCI 0.57 0.38–0
CABG 1.56 0.80–3
MACCE All 0.70 0.55–0
PCI 0.61 0.44–0
CABG 0.94 0.66–1
Incidences of Adverse Events Over 5 YearsTable 3 Incidences of Adverse Events Over 5 Years
PCI
Outcomes
IG
(n  322)
Non-IG
(n  2,265
Primary endpoint of MACCE 45 (17.4) 451 (22.8
Composite of death, MI, or stroke 23 (9.0) 179 (9.4)
Death 17 (6.4) 140 (7.4)
Cardiac 4 (1.8) 67 (3.6)
Noncardiac 13 (4.7) 73 (3.9)
MI 3 (0.9) 23 (1.2)
STEMI 2 (0.6) 8 (0.4)
NSTEMI 1 (0.3) 15 (0.7)
Repeat revascularization 26 (9.9) 291 (14.8
Target vessel 18 (7.2) 211 (10.8
Non-target vessel 8 (2.7) 80 (3.9)
Stroke 5 (2.5) 35 (1.9)
Hemorrhagic 1 (0.6) 7 (0.6)
Non-hemorrhagic 4 (1.9) 28 (1.5)
Stent thrombosis (definite or probable) 1 (0.3) 28 (1.3)
Definite 1 (0.3) 11 (0.5)
Probable 0 17 (0.8)
Values are n and Kaplan-Meier incidence of events. *p Values were analyzed with the log-rank tes
MACCE  major adverse cardiac and cerebrovascular event; STEMI  ST-segment elevation mCI  confidence interval; HR  hazard ratio; other abbreviations as in Tables 1 and 3.under-used, due to a paucity of data with regard to its role in
guiding optimal revascularization (16). We found that MPI
assessments were performed in fewer than 50% of revascular-
ized patients, even those with MVD.
In our large MVD registry, IG revascularization reduced
the risk of MACCE by 27%, driven by a 34% reduction in
ts
te Adjustment
Inverse-Probability-of-Treatment
Weighting Method
p Value
Interaction
p Value HR 95% CI p Value
Interaction
p Value
0.18 0.77 0.84 0.66–1.06 0.13 0.96
0.43 0.83 0.53–1.29 0.41
0.18 0.82 0.61–1.10 0.18
0.072 0.015 0.66 0.49–0.90 0.009 0.044
0.005 0.53 0.35–0.80 0.003
0.49 1.16 0.70–1.94 0.57
0.007 0.12 0.73 0.60–0.88 0.001 0.18
0.002 0.59 0.43–0.81 0.001
0.17 0.87 0.67–1.14 0.32
0.13 0.87 0.77 0.56–1.06 0.11 0.52
0.50 0.77 0.48–1.24 0.28
0.28 0.89 0.57–1.39 0.60
0.047 0.015 0.71 0.50–1.01 0.054 0.006
0.007 0.52 0.35–0.79 0.002
0.19 1.78 0.86–3.66 0.12
0.003 0.18 0.70 0.55–0.90 0.005 0.044
0.002 0.58 0.42–0.80 0.001
0.72 1.01 0.68–1.49 0.97
CABG
p Value*
IG
(n  600)
Non-IG
(n  2,153) p Value*
0.006 90 (16.0) 339 (18.5) 0.15
0.55 73 (13.1) 289 (15.7) 0.088
0.46 54 (9.6) 226 (12.2) 0.072
0.072 29 (5.4) 123 (7.0) 0.14
0.52 25 (4.5) 103 (5.6) 0.29
0.86 5 (1.0) 22 (1.2) 0.54
0.50 — 5 (0.3) 0.20
0.44 5 (1.0) 17 (0.9) 0.95
0.010 24 (4.3) 66 (3.9) 0.53
0.020 21 (3.8) 56 (3.4) 0.50
0.30 3 (0.5) 10 (0.6) 0.99
0.96 22 (4.1) 70 (4.1) 0.99
0.98 3 (0.6) 15 (0.9) 0.44
0.97 19 (3.5) 55 (3.2) 0.70
0.14 — — —
0.65 — — —
0.12 — — —
l infarction; other abbreviations as in Table 1.Even
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Ischemia-Guided Revascularization July 17, 2012:181–90repeat revascularization after adjustment. In particular, the
risk reductions in patients undergoing PCI were 47% for
repeat revascularization and 41% for MACCE. Our find-
Propensity Score Matching AnalysesTable 5 Propensity Score Matching Analyses
Groups
No. of
Matched Pairs
Repeat Revasculariza
HR (95% CI) p
Ischemia-guidance
Overall 919 0.72 (0.50–1.03)
PCI group 321 0.58 (0.36–0.91)
CABG group 596 1.16 (0.65–2.05)
Inter-groups
(D, E, F, G, H, and I) vs. J 2,176 0.80 (0.65–0.99)
(D, E, and F) vs. J 1,543 0.94 (0.50–1.03)
(G, H, and I) vs. J 700 0.67 (0.43–1.02)
(D and G) vs. J 915 0.68 (0.47–0.99)
(D and G) vs. (E and H) 842 0.75 (0.52–1.09)
Abbreviations as in Tables 1, 3, and 4.
Figure 3 Adjusted HRs for MACCE in Subgroups
CI  confidence interval; HR  hazard ratio; LAD  left anterior descending artery
other abbreviations as in Figure 1.ings were in line with those of the FAME study, which
showed that FFR-guided stenting significantly reduced the
risks of MACCE and repeat revascularization, compared
Death, MI, or Stroke MACCE
HR (95% CI) p Value HR p Value
0.98 (0.74–1.30) 0.90 0.82 (0.65–1.03) 0.085
0.82 (0.48–1.41) 0.47 0.61 (0.44–0.84) 0.003
0.99 (0.70–1.39) 0.94 1.02 (0.75–1.39) 0.91
1.18 (0.98–1.41) 0.079 0.997 (0.87–1.15) 0.96
1.27 (1.03–1.57) 0.026 1.12 (0.95–1.32) 0.17
1.24 (0.91–1.69) 0.18 0.96 (0.74–1.23) 0.74
0.89 (0.67–1.19) 0.44 0.76 (0.60–0.96) 0.023
0.75 (0.57–0.99) 0.046 0.71 (0.57–0.90) 0.004
AX  Synergy Between PCI With Taxus and Cardiac Surgery;tion
Value
0.075
0.019
0.62
0.039
0.61
0.060
0.042
0.13; SYNT
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July 17, 2012:181–90 Ischemia-Guided Revascularizationwith angiography-guided stenting for stable patients with
MVD (5). The superiority of IG revascularization was
primarily due to the weak correlation between morpholog-
ical severity and functional ischemia (17–19). The IG
stenting reduced the number of devices used as well as the
subsequent risks of acute and chronic events by avoiding
unnecessary procedures, both here and in the FAME study
(5). The risks of adverse events of DES cannot be avoided
when implanted into multiple lesions (20). Moreover, not
performing revascularization for ischemic areas might have
contributed to the unfavorable outcomes of non-IG revas-
cularization (15,21).
Ischemia guidance did not affect the clinical outcomes
after CABG, in contrast with PCI. Because anatomical
complete revascularization was often attempted in CABG by
anastomosing the bypass graft distal to the site of coronary
disease (2), functional evaluation with MPI might have had a
educed influence on operational technique and resultant
linical outcomes. The safety of IG—as reflected by the
ndpoints of death, MI, or stroke—was comparable to that of
on-IG after either PCI or CABG. This finding was in good
greement with previous studies, which showed very low
ncidences of death or MI in patients with nonischemic
oronary lesions, as evidenced by MPI or FFR (5,17,22).
Although our study confirmed the observations of the
AME study, the clinical implications of these 2 studies
hould be independently addressed (5,23). First, the 2
tudies had different study designs. In contrast with the
andomized FAME study, our analysis was performed with
ata derived from a large registry. Because clinical trials
nclude relatively healthy patients, the real benefits of IG
an be diluted in a randomized study (24). Second, our
study had a longer follow-up duration than the 2-year
follow-up in the FAME study (23). We found that the
curves for MACCE rate in the IG and non-IG groups
progressively diverged through 5 years. Moreover, although
the differences in MACCE rate were not statistically sig-
nificant, the curves started to diverge after 2 years in the
CABG group. Third, MPI and FFR each have unique
advantages and disadvantages. For example, although MPI
with SPECT has been reported to have a lower sensitivity
than FFR for detecting ischemic myocardium in MVD
patients, the practical sensitivity of SPECT might be
clinically sufficient to identify “clinically culprit vessels”
determining clinical outcomes (6,21). Moreover, MPI has
technical advantages, including its noninvasiveness and
universal applicability to all lesion subsets, including chronic
total occlusion, calcified lesions, and severely tortuous le-
sions, in which FFR assessment is practically difficult.
Study limitations. First, a match between the perfusion
abnormality and revascularized vessel for adjudication of IG
was roughly divided into LAD and non-LAD territories.
Further prospective studies with a pre-specified protocol to
define the ischemic territory will confirm the clinical benefit
of IG and clarify the mechanism of superiority. Second, we
did not combine information on reversibility and abnormalperfusion area in our analysis. Myocardial viability or
ischemic area might influence the results, regardless of the
type of revascularization treatment (25). Because our study
included all patients with or without MPI, further studies
are required to investigate this issue. Third, our study was
based on the experience of a large-volume center. Therefore,
it might not be possible to generalize our utility pattern and
findings on the clinical impact of MPI to other institutions.
Nonetheless, the similar rate of stress testing in a large U.S.
national registry indicates that our results might be widely
applicable in daily practices (16). Fourth, unobserved con-
founders might have biased our results, due to the nonran-
domized study design. In fact, high-risk patients who were
expected not to tolerate stress imaging tests might have been
included in the non-IG group. However, the concordant
results after vigorous 2-stage adjustments support their
reliability. Fifth, because of limited angiographic analysis,
we might not have completely adjusted for angiographic
factors. However, analyses in an independent angiographic
core laboratory of a large patient cohort strengthened the
objectivity of our findings and might overcome their limita-
tions. Sixth, our study used Tl-201, which might be more
susceptible to scatter or attenuation artifact than technetium.
However, both Tl-201 and technetium are considered com-
parable to assess the extent and severity of reversible perfusion
abnormalities (26). Finally, the 1-year time window of MPI
before revascularization might have influenced the true inci-
dence of abnormal tests and the impact of IG. This limitation
warrants further studies with a well-designed protocol for
pre-specified times of stress image tests, angiography, and
revascularization.
Conclusions
IG revascularization with MPI with SPECT seems to
reduce the risk of repeat revascularization and subsequent
MACCE, particularly in patients with MVD who undergo
PCI with DES. Our results might promote a better adher-
ence to clinical practice guidelines in the treatment of
patients with MVD.
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